These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30990229)

  • 1. A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension.
    Kay J
    J Intern Med; 2019 Jun; 285(6):693-695. PubMed ID: 30990229
    [No Abstract]   [Full Text] [Related]  

  • 2. The Experience with Biosimilars of Infliximab in Rheumatic Diseases.
    Azevedo VF; Kos IA; Ariello L
    Curr Pharm Des; 2017; 23(44):6752-6758. PubMed ID: 29189135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
    Katsanos KH; Papamichael K; Cheifetz AS; Christodoulou DK
    Inflamm Bowel Dis; 2018 Feb; 24(3):465-466. PubMed ID: 29462402
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health.
    Braun J; Kudrin A
    Biologicals; 2016 Jul; 44(4):257-266. PubMed ID: 27117857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
    Fiorino G; Ruiz-Argüello MB; Maguregui A; Nagore D; Correale C; Radice S; Gilardi D; Allocca M; Furfaro F; Martínez A; Danese S
    Inflamm Bowel Dis; 2018 Feb; 24(3):601-606. PubMed ID: 29462398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence studies with anti-TNF biosimilars.
    Gimeno-Gracia M; Gargallo-Puyuelo CJ; Gomollón F
    Expert Opin Biol Ther; 2019 Oct; 19(10):1031-1043. PubMed ID: 30574813
    [No Abstract]   [Full Text] [Related]  

  • 14. Uptake of rheumatology biosimilars in the absence of forced switching.
    Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
    Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of switching from two anti-TNF biosimilars back to biologic reference products in Germany
.
    Reuber K; Kostev K
    Int J Clin Pharmacol Ther; 2019 Jun; 57(6):323-328. PubMed ID: 30990409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
    Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The switch to infliximab biosimilars.
    Veselý R; Richardson P
    Lancet; 2017 Jun; 389(10086):2266-2268. PubMed ID: 28502608
    [No Abstract]   [Full Text] [Related]  

  • 20. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683.
    Gentileschi S; Barreca C; Bellisai F; Biasi G; Brizi MG; De Stefano R; Fabbroni M; Fioravanti A; Frati E; Selvi E; Vitale A; Cantarini L; Frediani B; Galeazzi M
    Expert Opin Biol Ther; 2016 Oct; 16(10):1311-2. PubMed ID: 27266338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.